Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of Switching to Cabotegravir Ultra Long-acting in Healthy Adults
NCT06786520Phase 1Active, not recruiting
- Sponsor
- ViiV Healthcare
- Start
- Jan 2025
- Primary completion
- Mar 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of cabotegravir in human immunodeficiency virus infection (HIV), sponsored by ViiV Healthcare. Primary endpoint: Plasma concentration of CAB at the end of the CAB LA phase compared to plasma concentration of CAB at the end of the CAB ULA phase. Started Jan 2025; status: active, not recruiting.
02
Drugs
cabotegravir
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT06786520.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06786520.